WO2023249469A1 - Nouveau dérivé de thalidomide et son procédé de production - Google Patents

Nouveau dérivé de thalidomide et son procédé de production Download PDF

Info

Publication number
WO2023249469A1
WO2023249469A1 PCT/KR2023/008836 KR2023008836W WO2023249469A1 WO 2023249469 A1 WO2023249469 A1 WO 2023249469A1 KR 2023008836 W KR2023008836 W KR 2023008836W WO 2023249469 A1 WO2023249469 A1 WO 2023249469A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
present
acid
chloride
Prior art date
Application number
PCT/KR2023/008836
Other languages
English (en)
Korean (ko)
Inventor
김동석
황인호
김선
Original Assignee
주식회사 아이비스바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 아이비스바이오 filed Critical 주식회사 아이비스바이오
Publication of WO2023249469A1 publication Critical patent/WO2023249469A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel thalidomide derivatives and methods for their preparation.
  • Thalidomide was a drug sold from the late 1950s to the 1960s to prevent morning sickness in pregnant women, but as teratogenic side effects were reported, its use and handling was prohibited for pregnant women, as well as people of childbearing age or those likely to become pregnant (Lancet) .2004 May 29;363(9423):1802-11). However, interest in the drug increased again after thalidomide was found to be clinically effective in the treatment of erythema nodosum (ENL), HIV wasting syndrome, and various cancers.
  • ENL erythema nodosum
  • Anti-tumor necrosis factor alpha activity was confirmed from mechanistic studies on ENL activity. Specifically, thalidomide increases the degradation of TNF- ⁇ RNA, thereby reducing its synthesis and secretion. Further studies have shown that it is a known co-stimulator of both CD8+ and CD4+ T cells and may also act as an angiogenesis inhibitor as an inhibitor of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and the transcription factor NF ⁇ B. It turns out.
  • bFGF basic fibroblast growth factor
  • VEGF vascular endothelial growth factor
  • TNF- ⁇ and its family members play a pivotal role in various physiological and pathological processes, including cell proliferation and differentiation, apoptosis, regulation of immune responses, and induction of inflammation.
  • TNF- ⁇ acts through two receptors, TNFR1 and 2, the former of which is expressed in all tissues and is the main signaling receptor for TNF- ⁇ . The latter is mainly expressed in immune cells and mediates more limited biological responses.
  • the caspase cascade can be activated, leading to cell death through apoptosis.
  • the main cell surface molecules that can initiate apoptosis are the ligands and receptors of TNF family members.
  • each death-inducing member of the TNF receptor family contains a cytoplasmic 'death domain' (DD), a protein-protein interaction motif that is important for binding to downstream components of the signaling machinery.
  • DD cytoplasmic 'death domain'
  • TRAIL a tumor necrosis factor-related apoptosis-inducing ligand
  • TRAIL a tumor necrosis factor-related apoptosis-inducing ligand
  • TNF- ⁇ has been implicated in many inflammatory diseases, such as rheumatoid arthritis, graft-versus-host disease, and Crohn's disease, and is known to further exacerbate dementias associated with ENL, septic shock, AIDS, and Alzheimer's disease (AD). .
  • thalidomide-based treatments include thalidomide, bortezomib, lenalidomide, and pomalidomide.
  • the injectable drug bortezomib is steadily maintaining its market and growing, and the oral drug is taking over the existing thalidomide position. Domide has replaced it and is recording high growth in the market.
  • Lenalidomide is the next-generation drug of thalidomide and shows better therapeutic effects than thalidomide through more powerful cancer cell killing and immune regulation.
  • the combined treatment of lenalidomide and dexamethasone is known to be quite effective, with a disease-free survival of 13.4 months and an overall survival of 38 months.
  • Pomalidomide directly inhibits angiogenesis and myeloma cell growth, and this dual effect is centered on its activity in myeloma rather than on other pathways such as TNF- ⁇ inhibition.
  • pomalidomide exhibits anti-angiogenic and anti-myeloma activities.
  • the present inventors have made diligent efforts to develop new derivatives of thalidomide with improved cereblon binding properties. As a result, among various derivatives, derivatives with aspirin attached to lenalidomide and pomalidomide have enhanced cereblon binding properties and suppress bone marrow cells. The present invention was completed by confirming that reproductive toxicity such as teratogenic side effects was reduced.
  • the purpose of the present invention is to provide a novel thalidomide derivative with improved cereblon binding ability and a method for producing the same.
  • the present invention provides a compound of either [Formula 1] or [Formula 2]:
  • the compound of [Formula 1] may be characterized as having improved cereblon binding ability compared to lenalidomide.
  • the compound [Formula 1] may be characterized as being non-teratogenic compared to lenalidomide.
  • the compound of [Formula 2] may be characterized as having improved cereblon binding ability compared to pomalidomide.
  • the compound of [Formula 2] may be characterized as being non-teratogenic compared to pomalidomide.
  • the present invention also provides a method for producing a compound [Formula 1] comprising the following steps:
  • step (a) acetylsalicylic acid may be dissolved in dichloromethane and reacted with oxaline chloride.
  • step (a) may be characterized by adding N,N-dimethylformamide and reacting under a nitrogen atmosphere.
  • step (b) may be characterized in that lenalidomide is dissolved in dioxane and reacted.
  • step (b) may be characterized by reacting at 15 to 30°C.
  • the production method may further include the step of purifying the compound [Formula 1] after step (b).
  • the present invention also provides a method for producing a compound [Formula 2] comprising the following steps:
  • step (a) acetylsalicylic acid may be dissolved in dichloromethane and reacted with oxaline chloride.
  • step (a) may be characterized by adding N,N-dimethylformamide and reacting under a nitrogen atmosphere.
  • step (b) may be characterized in that pomalidomide is dissolved in dioxane and reacted.
  • step (b) may be characterized by cooling after reaction at 70 to 100°C.
  • the production method may further include the step of purifying the compound [Formula 2] after step (b).
  • the novel thalidomide derivative developed in the present invention has the advantage of being able to be developed as a therapeutic agent that can replace existing thalidomide derivatives, as it has excellent binding ability to Cereblon, has little cytotoxicity, and has a low possibility of teratogenic side effects. .
  • Figure 1a shows the results of comparing the cereblon binding activity of the compound of Formula 1 with lenalidomide through a competitive inhibition reaction in vitro .
  • Figure 1b shows the results of comparing the cereblon binding activity of the compound of Formula 2 with pomalidomide through a competitive inhibition reaction in vitro .
  • Figure 2a shows the results of comparing the cytotoxicity of the compound of Formula 1 to MM.1S cell line with that of lenalidomide.
  • Figure 2b shows the results of comparing the cytotoxicity of the compound of Formula 2 to the MM.1S cell line with pomalidomide.
  • Figure 3 shows the results of treating the MM.1S cell line with the compound of Formula 1 and the compound of Formula 2, and confirming the intracellular Ikaros and Aiolos degradation effect by immunoblotting.
  • Figure 4a shows the results of treating Tera-1 cells with the compound of Formula 1 and comparing the degree of intracellular SALL4 degradation with lenalidomide by immunoblotting.
  • Figure 4b shows the results of treating Tera-1 cells with the compound of Formula 2 and comparing the degree of intracellular SALL4 degradation with pomalidomide by immunoblotting.
  • derivatives were developed by combining aspirin with lenalidomide and pomalidomide, respectively, and the new compounds developed in this way have enhanced cereblon binding ability and reduced reproductive toxicity compared to lenalidomide or pomalidomide, respectively. It has been confirmed that this can be done.
  • the present invention in one aspect, relates to the compound [Formula 1]:
  • the compound of [Formula 1] may be characterized as having improved cereblon binding ability compared to lenalidomide.
  • the compound [Formula 1] may be characterized as being non-teratogenic compared to lenalidomide.
  • the compound of [Formula 2] may be characterized as having improved cereblon binding ability compared to pomalidomide.
  • the compound of [Formula 2] may be characterized as being non-teratogenic compared to pomalidomide.
  • the present invention relates to a method for producing a compound [Formula 1] comprising the following steps:
  • step (a) acetylsalicylic acid may be dissolved in dichloromethane and reacted with oxaline chloride.
  • step (a) may be characterized by reacting acetylsalicylic acid and oxaline chloride at a molar ratio of 1:0.5 to 4, preferably about 1:2.
  • step (a) may be characterized by adding N,N-dimethylformamide and reacting under a nitrogen atmosphere.
  • step (a) may be characterized by reacting at about -2 to 4°C for 5 minutes to 1 hour, followed by stirring at room temperature for 30 minutes to 3 hours.
  • step (a) may be characterized in that acid chloride of [Formula I] is produced by concentration after stirring.
  • step (b) may be characterized in that lenalidomide is dissolved in dioxane and reacted.
  • the lenalidomide in step (b) is added at a molar ratio of 1:0.5 to 2, preferably about 1:1, relative to the acetylsalicylic acid used in step (a). can do.
  • N,N-diisopropylethylamine in step (b) is added at a molar ratio of 1:2 to 4, preferably about 1:3, relative to lenalidomide. can do.
  • step (b) may be characterized as reaction at 15 to 30°C, and preferably at room temperature.
  • step (b) may be characterized by stirring for 1 hour to 5 hours, for example, 2 hours to 4 hours, preferably about 3 hours.
  • step (b) may further include the step of concentrating after stirring, and the concentration may be concentrated using a rotary evaporator, but is not limited thereto.
  • the production method may further include the step of purifying the compound [Formula 1] after step (b).
  • the crude product may be subsequently concentrated and purified by chromatography.
  • the present invention relates to a method for preparing a compound of [Formula 2] comprising the following steps:
  • step (a) acetylsalicylic acid may be dissolved in dichloromethane and reacted with oxaline chloride.
  • step (a) may be characterized by reacting acetylsalicylic acid and oxaline chloride at a molar ratio of 1:0.5 to 4, preferably about 1:2.
  • step (a) may be characterized by adding N,N-dimethylformamide and reacting under a nitrogen atmosphere.
  • step (a) may be characterized by reacting at about -2 to 4°C for 5 minutes to 1 hour, followed by stirring at room temperature for 30 minutes to 3 hours.
  • step (b) may be characterized in that pomalidomide is dissolved in dioxane and reacted.
  • the pomalidomide in step (b) is added at a molar ratio of 1:0.5 to 1, preferably about 1:0.8, compared to the acetylsalicylic acid used in step (a). You can.
  • the N,N-diisopropylethylamine in step (b) is characterized in that it is added at a molar ratio of 8:20 to 40, preferably about 8:30, compared to pomalidomide. You can.
  • step (b) may be characterized by stirring overnight at about 60 to 100°C, for example, about 70 to 90°C, preferably 80°C, then cooling to room temperature and concentrating. Thereafter, step (b) may be characterized by adding ethyl acetate, washing with water, and concentrating. The concentration may be concentrated using a rotary evaporator, but is not limited thereto.
  • the production method may further include the step of purifying the compound [Formula 2] after step (b).
  • the purification may be characterized by purification by chromatography.
  • chromatography means a method for separating and purifying the compounds of the invention, wherein a solution containing the compounds of the invention is passed using a liquid stream over a stationary phase, and the components of the mixture are fractionated. I get angry.
  • the stationary phase is preferably the packing material in the chromatography column.
  • the filling material hereinafter also referred to as the so-called gel material, preferably consists of a solid support material consisting of porous or non-porous particles of approximately equal size, on which functional groups that establish the mode of separation are covalently bonded.
  • Support materials can be biopolymers such as, for example, agarose, cellulose and dextran (preferably Sepharose and Sephadex), or polymers such as, for example, methacrylates, polyvinylbenzene, polystyrene and polyacrylamide. It may be a synthetic polymer or an inorganic polymer such as, for example, silica or porous glass beads.
  • the chromatography may be selected from the group consisting of hydrophobic interaction chromatography (HIC), ion exchange chromatography (IEC), size exclusion chromatography (SEC), affinity chromatography, and reversed phase chromatography. , but is not limited to this.
  • HIC hydrophobic interaction chromatography
  • IEC ion exchange chromatography
  • SEC size exclusion chromatography
  • affinity chromatography affinity chromatography
  • reversed phase chromatography reversed phase chromatography
  • UF ultrafiltration
  • DF diafiltration
  • concentrated under reduced pressure in order to further purify and/or concentrate the compound, it can be selectively subjected to ultrafiltration (UF), diafiltration (DF), or concentrated under reduced pressure.
  • the compound may be used as an active ingredient in a pharmaceutical composition such as a cereblon combination therapeutic agent, depending on its ability to bind to cereblon and its properties to reduce reproductive toxicity such as myeloid cell suppression or teratogenic side effects.
  • a pharmaceutical composition such as a cereblon combination therapeutic agent, depending on its ability to bind to cereblon and its properties to reduce reproductive toxicity such as myeloid cell suppression or teratogenic side effects.
  • compositions of the present invention refers to a pharmaceutical agent, such as a diluent or carrier, that makes the novel compound of the present invention particularly suitable for in vivo or in vitro diagnostic or therapeutic use. It refers to a mixture containing acceptable excipients.
  • a pharmaceutical composition containing the composition of the present invention may be provided by administering a therapeutically effective amount to a subject according to need.
  • compositions of the present invention can be administered to humans.
  • an effective amount refers to the amount of a compound or composition (e.g., a compound or composition of the invention) sufficient to achieve a beneficial or desired result. Refers to an amount.
  • An effective amount may be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular agent or route of administration.
  • compositions provided by the present invention relate in principle to pharmaceutical compositions for administration to humans, those skilled in the art will understand that such compositions are generally suitable for administration to all types of animals. That is, the pharmaceutical composition according to the present invention is suitable for use in animals requiring veterinary treatment, such as livestock (e.g., dogs, cats, etc.), farm animals (e.g., cows, sheep, pigs, horses, etc.) and laboratory animals. It can also be administered to other mammals such as rats, mice, guinea pigs, etc. A skilled veterinary pharmacologist with a good understanding of the modifications of pharmaceutical compositions for administration to various animals can design and/or perform such modifications, if necessary, simply by routine experimentation.
  • livestock e.g., dogs, cats, etc.
  • farm animals e.g., cows, sheep, pigs, horses, etc.
  • laboratory animals e.g., cows, sheep, pigs, horses, etc.
  • laboratory animals e.g., cows, sheep, pigs,
  • compositions described in the present invention may be prepared by any method known in the field of pharmacology or as discussed later in the text. Generally, these methods for tableting involve the steps of associating the active ingredient with excipients and/or one or more other auxiliary ingredients, followed by shaping and/or packaging the product into the desired single- or multi-dose units, if necessary or desired. Includes steps.
  • compositions of the present invention may be manufactured, packaged, and/or sold unpackaged as a single unit dose and/or multiple single unit doses.
  • a “unit dose” is a discrete amount of a pharmaceutical composition containing a predetermined amount of an active ingredient.
  • the amount of active ingredient is generally equal to the dosage of active ingredient administered to the subject and/or a convenient fraction of such dosage such as, for example, one-half or one-third of the dosage.
  • compositions of the invention will vary depending on the identity, size, and/or disorder of the subject being treated and the route by which the composition is administered. .
  • the composition may include 0.001% to 100% (w/w) active ingredient.
  • a pharmaceutically acceptable excipient is any solvent, dispersion medium, diluent, or other liquid vehicle, dispersion or suspension aid, surface active agent, isotonic agent, thickener or emulsifier suitable for the purpose of the particular dosage form; Contains preservatives, solid binders, lubricants, etc.
  • Remington's The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro, (Lippincott, Williams & Wilkins, Baltimore, MD, 2006) describes various excipients used in the preparation of pharmaceutical compositions and known methods for their preparation.
  • any conventional carrier medium is incompatible with the substance or derivative thereof, for example by providing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component of the pharmaceutical composition. and their uses are considered to be within the scope of the present invention.
  • Pharmaceutically acceptable excipients are at least 95%, 96%, 97%, 98%, 99%, or 100% pure.
  • the excipients are approved for human and veterinary use. In some embodiments, the excipient is approved by the Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient meets the standards of the United States Pharmacopeia (USP), European Pharmacopoeia (EP), British Pharmacopoeia, and/or International Pharmacopoeia (EP).
  • USP United States Pharmacopeia
  • EP European Pharmacopoeia
  • EP British Pharmacopoeia
  • EP International Pharmacopoeia
  • compositions include, but are not limited to, inert diluents, dispersants and/or granulating agents, surface active agents and/or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants, and/or oils. Not limited.
  • excipients may optionally be included in the formulations of the present invention.
  • Excipients such as cocoa butter and suppository waxes, colorants, coating agents, sweeteners, flavors, and perfumers may be present in the composition at the discretion of the formulator.
  • Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dried starch, Including, but not limited to, corn starch, powdered sugar, and combinations thereof.
  • Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponges, cation-exchange resins.
  • Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and veegum [magnesium aluminum silicate]), long-chain amino acid derivatives, high molecular weight alcohols (e.g.
  • natural emulsifiers e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin
  • colloidal clays e.g. bentonite [aluminum silicate] and veeg
  • stearyl alcohol cetyl alcohol, oleyl alcohol
  • triacetin monostearate ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate
  • polyvinyl alcohol polyvinyl alcohol
  • carbomers e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymers
  • carrageenans e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose
  • sorbitan fatty acid esters e.g.
  • polyoxyethylene monostearate [mirz 45]) , polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. cremophor), polyoxyethylene ethers, ( For example, polyoxyethylene lauryl ether [Brise 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl.
  • Exemplary binders include starches (e.g. corn starch and starch paste); gelatin; sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); Natural and synthetic gums (e.g.
  • acacia sodium alginate, extract of Irish moss, Farnwer gum, Shatty gum, Isapol Husk's slime, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl) cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (bigum), and lachi arabogalactan); alginate; polyethylene oxide; polyethylene glycol; inorganic calcium salt; silicic acid; polymethacrylate; wax; water; Alcohol; and combinations thereof.
  • Exemplary preservatives may include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
  • Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, bisulfite. Including, but not limited to, sodium sulfate, sodium metabisulfite, and sodium sulfite.
  • Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, disodium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and trisodium edetate. .
  • EDTA ethylenediaminetetraacetic acid
  • citric acid monohydrate disodium edetate
  • disodium edetate disodium edetate
  • edetic acid fumaric acid, malic acid
  • phosphoric acid sodium edetate
  • tartaric acid tartaric acid
  • trisodium edetate trisodium edetate.
  • Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, Includes, but is not limited to, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
  • Exemplary antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
  • Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
  • Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
  • preservatives include tocopherol, tocopherol acetate, deteroxyme mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluende (BHT), ethylenediamine, sodium lauryl sulfate (SLS), Sodium Lauryl Ether Sulfate (SLES), Sodium Bisulfite, Sodium Metabisulfite, Potassium Sulfite, Potassium Metabisulfite, Glydant Plus, Fenonib, Methylparaben, Low Mol 115, Germaben II, Neolon, Katon, and E Including, but not limited to, Uxil.
  • the preservative is an antioxidant.
  • the preservative is a chelating agent.
  • Exemplary buffering agents include citrate buffer solution, acetate buffer solution, phosphate buffer solution, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium gluvionate, calcium gluceptate, calcium gluconate, D-gluconic acid, glyceroside.
  • Exemplary lubricants include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oil, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium. Including, but not limited to, lauryl sulfate, and combinations thereof.
  • oils include almond, apricot kernel, avocado, babassu palm, bergamot, black currant seed, borage, cayenne, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee. , corn, cotton seed, emu, eucalyptus, evening primrose, fish, flax seed, geraniol, pumpkin, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litthea cucumber.
  • oils include butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil. , and combinations thereof.
  • Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.
  • liquid dosage forms may contain inert diluents such as, for example, water or other solvents, solubilizers and emulsifiers commonly used in the art such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl.
  • compositions may include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • novel compounds of the invention are mixed with solubilizing agents such as cremophor, alcohols, oils, denatured oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.
  • solubilizing agents such as cremophor, alcohols, oils, denatured oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.
  • Injectable preparations for example, sterile injectable aqueous or oily suspensions, may be prepared according to the known art using dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may be a sterile injectable solution, suspension or emulsion in a non-toxic parenterally acceptable diluent or solvent, such as solution in 1,3-butanediol.
  • a non-toxic parenterally acceptable diluent or solvent such as solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are commonly employed as solvents or suspending media.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid have been used in the preparation of injectables.
  • Injectable preparations may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating a sterilizing agent in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. .
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active ingredient may be combined with one or more inert pharmaceutically acceptable excipients or carriers such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol, and silicic acid, b ) binders such as, for example, carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrants such as agar, calcium carbonate, potato or tapioca starch.
  • inert pharmaceutically acceptable excipients or carriers such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol, and silicic acid
  • b binders
  • alginic acid alginic acid, certain silicates, and sodium carbonate
  • dissolution retarders such as paraffin
  • absorption accelerators such as quaternary ammonium compounds
  • humectants such as, for example, cetyl alcohol and glycerol monostearate
  • absorbents such as kaolin and bentonite clay
  • lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof.
  • dosage forms may contain buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose or milk sugar as well as high molecular weight polyethylene glycols and the like as such excipients.
  • Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They may optionally contain opacifying agents and may be compositions that release the active ingredient only, or preferentially, in a specific part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose or milk sugar as well as high molecular weight polyethylene glycols and the like as such excipients.
  • the active ingredient may be in micro-encapsulated form with one or more of the excipients described above.
  • Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, controlled release coatings, and other coatings well known in the pharmaceutical formulation art.
  • the active ingredient may be mixed with one or more inert diluents such as sucrose, lactose or starch.
  • These dosage forms may contain additional substances other than inert diluents as in common practice, such as tablet lubricants and other tablet auxiliaries such as magnesium stearate and microcrystalline cellulose.
  • dosage forms may also contain buffering agents.
  • opacifying agents may optionally contain opacifying agents and may be compositions that release the active ingredient only, or preferentially, in a specific part of the intestinal tract, optionally in a delayed manner.
  • embedding compositions include polymeric substances and waxes.
  • Dosage forms for topical and/or transdermal administration of the novel compounds of the present invention or pharmaceutical compositions containing them may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches. .
  • the active ingredient is admixed under conditions of sterility with a pharmaceutically acceptable carrier and/or any necessary preservatives and/or buffering agents that may be required.
  • the present invention contemplates the use of transdermal patches, which often have the additional advantage of providing controlled delivery of the active ingredient to the body.
  • Such dosage forms can be prepared, for example, by dissolving and/or dispersing the active ingredient in a suitable medium.
  • the rate may be controlled by providing a rate controlling membrane and/or dispersing the active ingredient in a polymer matrix and/or gel.
  • Formulations for topical administration include, but are not limited to, liquid and/or semi-liquid preparations such as liniments, lotions, oil-in-water and/or water-in-oil emulsions such as creams, ointments/or pastes, and/or solutions and/or suspensions.
  • concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent
  • topically-administrable formulations may also comprise, for example, from about 1% to about 10% (w/w) of the active ingredient.
  • Formulations for topical administration may further comprise one or more additional ingredients described herein.
  • novel compounds of the invention described herein or pharmaceutical compositions containing them are typically prepared in dosage unit form for easy administration and uniform administration.
  • the total daily dosage of the composition of the present invention will be determined by the attending physician within the scope of sound medical judgment.
  • the particular therapeutically effective dose level for any particular subject will depend on a variety of factors, including the disease, disorder, or disorder being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; The subject's age, weight, general health, gender, and diet; the time of administration, route of administration, and rate of excretion of the particular active ingredient employed; duration of treatment; Drugs used in combination or simultaneously with the specific active ingredients employed; and factors well known in the medical field.
  • novel compound of the present invention, its salt, or pharmaceutical composition may be administered by any route.
  • the novel compound, salt thereof, or pharmaceutical composition thereof may be administered orally, intravenously, intramuscularly, intraarterially, intramedullarily, intrathecally, subcutaneously, intracerebroventricularly, transdermally, intradermally, rectally, intravaginally, intraperitoneally, Topically (by powder, ointment, cream, and/or drop), mucosal, nasal, oral, enteral, sublingual; endotracheal instillation, bronchial instillation, and/or inhalation; and/or administered by various routes, including oral spray, nasal spray, and/or aerosol.
  • Particularly contemplated routes are permeable intravenous injection, local administration via the blood and/or lymphatic supply, and/or direct administration to the affected area.
  • the most appropriate route of administration will depend on a variety of factors, including the properties of the agent (e.g., stability in the environment of the gastrointestinal tract), and the disorder of the subject (e.g., whether the subject can tolerate oral administration). will be.
  • novel compound of the present invention or its salt may be included in an amount of 0.001 to 99.9% of the total weight of the pharmaceutical composition.
  • the novel compound of the present invention, salt thereof, or pharmaceutical composition thereof is administered in an amount of about 0.001 mg/kg to about 100 mg/kg, about 0.01 mg/kg to about 50 mg/kg, or about 0.1 mg/kg of the subject's body weight per day. mg/kg to about 40 mg/kg, about 0.5 mg/kg to about 30 mg/kg, about 0.01 mg/kg to about 10 mg/kg, about 0.1 mg/kg to about 10 mg/kg, or about 1 mg. /kg to about 25 mg/kg may be administered at a dosage level sufficient to deliver once or more per day to achieve the desired therapeutic effect.
  • the intended dosage may be delivered three times a day, twice a day, daily, every two days, every three days, weekly, every two weeks, every three weeks, or every four weeks.
  • the desired dosage may be delivered via multiple administrations (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more administrations). .
  • the dosage ranges described herein provide guidance for administration of pharmaceutical compositions provided to adults.
  • the amount administered to a child or adolescent may be determined by a physician or person skilled in the art, and may be less or the same as that administered to an adult.
  • the exact amount of a peptide according to the invention required to achieve an effective amount will vary from subject to subject, depending, for example, on the subject's species, age, and overall disorder, severity of side effects or disorders, identity of the specific compound, mode of administration, etc.
  • novel compounds and pharmaceutical compositions of the present invention can be used in combination therapy.
  • the particular combination of treatments (treatments or procedures) for use in combination therapy will take into account the desired therapeutic effect to be achieved and the suitability of the desired treatments and/or procedures.
  • the pharmaceutical composition of the present invention can be administered alone or in combination with one or more therapeutically active agents.
  • “combination” it is not intended to imply that the agents must be administered at the same time and/or be formulated for delivery together, although the following delivery methods are within the scope of the present invention.
  • the composition may be administered concurrently with, prior to, or subsequent to one or more other therapeutic agents or medical procedures. Generally, each agent will be administered at a dose and/or time schedule established for that agent.
  • the present invention provides a pharmaceutical form of the present invention in combination with agents capable of improving its bioavailability, reducing and/or modifying its metabolism, inhibiting its secretion, and/or modifying its distribution within the body. It encompasses delivering the composition. It will be further understood that the novel compound of the invention and the therapeutically active agent used in this combination may be administered together in a single composition or may be administered separately in different compositions.
  • the particular combination used in combination therapy will take into account the desired therapeutic effect to be achieved and/or the suitability of the procedure and/or therapeutically active agent comprising the peptide of the invention.
  • the combination used may achieve the desired effect for the same disorder (e.g., a novel compound of the invention may be administered in combination with another therapeutically active agent (e.g., a second therapeutic agent) used to treat the same disorder. It will be understood that they may achieve different effects (e.g., control of any side effects), and/or they may achieve different effects (e.g., control of any side effects).
  • therapeutically active agent refers to any substance used as a medicine to treat, prevent, delay, reduce or ameliorate a disorder, and refers to substances used in treatment, including prophylactic and curative treatments. .
  • the pharmaceutical compositions of the invention treat, alleviate, ameliorate, alleviate, delay the onset, inhibit the progression, reduce the severity, and/or the incidence of one or more symptoms or characteristics.
  • the compound of the present invention can be provided as a kit for treating diseases.
  • the kit comprises i) instructions for administering the novel compound or pharmaceutical composition according to the invention to a subject suffering from a disease, and ii) the novel compound or pharmaceutical composition according to the invention.
  • the kit may include one or more unit dosage forms containing a dose of the novel compound or pharmaceutical composition as described herein that is effective for treating a disease in a subject.
  • the subject is a human patient.
  • the kit further includes one or more selected from the group comprising a sterile syringe, a sterile needle, a sterile IV bag, an infusion pump, or any combination thereof.
  • “Individual,” “patient,” and “subject” are used interchangeably and refer to mammals, such as mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, and sheep. , horses, or any animal, including primates, including humans.
  • treatment means reversing, alleviating, inhibiting the progression of, or preventing the disease or disease to which the term applies, or one or more symptoms of the disease or disease.
  • treatment refers to the act of treating when “treating” is defined as above. Accordingly, “treatment” or “therapy” of a disease in a mammal may include one or more of the following:
  • prevention means any action that suppresses or delays the onset of a disease by administering the pharmaceutical composition according to the present invention.
  • Pomalidomide used in the present invention is known as (R,S)-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione, [Chemical formula] II].
  • Lenalidomide used in the present invention is (R, S)-3-(4-amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6- It is known as a dione and can be characterized as being represented by [Chemical Formula III].
  • Oxalyl chloride (TCI, O0082) (282 mg, 2.22 mg) in a 0°C solution of acetylsalicylic acid (Daejeong Chemical, 1206-4425) (200 mg, 1.11 mmol) dissolved in dichloromethane (Samchun, M0822) (5 mL). mmol) and N,N-dimethylformamide (Samchun, D0552) (1 drop) were added under a nitrogen atmosphere, and stirred at 0°C for 20 minutes and at room temperature for 1 hour under a nitrogen atmosphere. Afterwards, the reaction mixture was concentrated using a rotary evaporator (EYELA, N-1300) to obtain crude acid chloride.
  • EYELA rotary evaporator
  • LENAsp (94.0 mg, 21%, T0036-21), a compound of Formula 1, was obtained as a white solid.
  • Thalidomide-based compounds are known to regulate the function of immune cells and exert various pharmacological effects by binding to Cereblon (CRBN), an E3 ligase, and decomposing the transcription factors Aiolos and Ikaros as its substrates. Accordingly, the cereblon binding ability of compounds of Formula 1 and Formula 2 was compared with lenalidomide or pomalidomide, respectively, in vitro .
  • the binding force to Cereblon was measured using the 'AlphaScreen' method based on Fluorescence Resonance Energy Transfer (FRET), and the test was performed using the PROTAC Optimization kit for BET Bromodomain-Cereblon binding kit (#79770, BPS bioscience, CA USA). It was carried out according to the 'Competitive Inhibition of the PROTAC assay' written in the manual in the kit. All reagents except the candidate substance, DMSO, and Flag/Glutathione beads (#6765300, PerkinElmer, USA) were used as those included in the kit.
  • FRET Fluorescence Resonance Energy Transfer
  • the compound of formula 1 according to the present invention has a significantly better binding ability to cereblon than lenalidomide
  • the compound of formula 2 according to the present invention has cereblon better than pomalidomide. It was confirmed that the binding ability to blow was remarkably excellent.
  • MM.1S cell line a human multiple myeloma cell line, was treated with compounds of Formula 1 and Formula 2, respectively, at different concentrations, and cytotoxicity was evaluated.
  • MM.1S (CRL-2974), a human multiple myeloma cell line, was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA), 10% fetal bovine serum (Corning, MD, USA), 100 U/ Cultivated for 24 hours in an incubator at 37°C and 5% CO 2 using RPMI1640 medium (Corning, MD, USA) supplemented with ml penicillin (Corning, MD, USA) and 100 ⁇ g/ml streptomycin (Corning, MD, USA). did. Cells were distributed in a 96-well plate at 1 Analysis was performed according to the manufacturer's manual. As a control group, lenalidomide or pomalidomide was treated at the same concentration.
  • Thalidomide-based compounds are known to regulate the function of immune cells by binding to Cereblon (CRBN), an E3 ligase, and decomposing the transcription factors Aiolos and Ikaros as its substrates.
  • CRBN Cereblon
  • E3 ligase an E3 ligase
  • the MM.1S cell line was supplemented with 10% fetal bovine serum (Corning, MD, USA), 100 U/ml penicillin (Corning, MD, USA), and 100 ⁇ g/ml streptomycin (Corning, MD, USA).
  • RPMI medium (Corning, MD, USA) was used and cultured at 37°C in a 5% CO 2 incubator.
  • Cells were distributed in 12-well plates at 1 , cells were disrupted by adding RIPA buffer containing protease inhibitor cocktail (Thermo Fisher Scientific), and centrifuged at 14,000 rpm for 15 minutes at 4°C to obtain cell extract. The same amount of cell extract was loaded, separated using SDS-PAGE, and transferred to a PVDF membrane.
  • the protein-transferred membrane was blocked using skim milk, incubated with primary antibody at room temperature for 3 hours, and then incubated with HRP-attached secondary antibody at room temperature for 1 hour. Washed three times with TBS-T between each step. Detection was performed by applying a chemoluminescence reagent (Thermo Fisher Scientific) and confirmed using Chemidoc (iBright CL1500, Invitrogen, CA, USA). Aiolos (#15103), Ikaros (#9034), and GAPDH (#2118S) antibodies used as primary antibodies and secondary antibodies were purchased from Cell signaling technology (Danvers, MA, USA).
  • Tera-1 cell line (HTB-105), a human embryonic carcinoma cell line, was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA), 10% fetal bovine serum (Corning, MD, USA), DMEM medium (Corning, MD, USA) supplemented with 100 U/ml penicillin (Corning, MD, USA) and 100 ⁇ g/ml streptomycin (Corning, MD, USA) was used at 37°C in a 5% CO 2 incubator. Cultured.
  • Cells were distributed at 5 ⁇ 10 5 cells/well in a 12-well plate and cultured for 24 hours, then treated with 1 or 10 ⁇ M of the compound of Formula 1 or Formula 2 and cultured for an additional 4 hours.
  • Cells were disrupted by adding RIPA buffer containing protease inhibitor cocktail (Thermo Fisher Scientific), and centrifuged at 14,000 rpm for 15 minutes at 4°C to obtain cell extract. The same amount of cell extract was loaded, separated using SDS-PAGE, and transferred to a PVDF membrane. The protein-transferred membrane was blocked using skim milk, incubated with primary antibody at room temperature for 3 hours, and then incubated with HRP-attached secondary antibody at room temperature for 1 hour. Washed three times with TBS-T between each step.
  • Detection was performed by applying a chemoluminescence reagent (Thermo Fisher Scientific) and confirmed using Chemidoc (iBright CL1500, Invitrogen, CA, USA).
  • SALL4 (#5850) and GAPDH (#2118S) antibodies used as primary antibodies and secondary antibodies were purchased from Cell signaling technology (Danvers, MA, USA).
  • both compounds of Formula 1 and Formula 2 according to the present invention reduce SALL4 protein less than lenalidomide or pomalidomide, respectively, and thus teratogenic side effects can be reduced. It was confirmed that it exists.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un nouveau dérivé de thalidomide développé dans l'invention a une excellente capacité de liaison par rapport au céréblon, n'a presque pas de cytotoxicité, et est peu susceptible de provoquer des effets secondaires tératogènes, et, a ainsi l'avantage de pouvoir être développé en tant qu'agent thérapeutique qui peut remplacer des dérivés de thalidomide classiques.
PCT/KR2023/008836 2022-06-24 2023-06-26 Nouveau dérivé de thalidomide et son procédé de production WO2023249469A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2022-0077698 2022-06-24
KR20220077698 2022-06-24

Publications (1)

Publication Number Publication Date
WO2023249469A1 true WO2023249469A1 (fr) 2023-12-28

Family

ID=89380307

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2023/008837 WO2023249470A1 (fr) 2022-06-24 2023-06-26 Nouveaux dérivés de pomalidomide et leur procédé de préparation
PCT/KR2023/008836 WO2023249469A1 (fr) 2022-06-24 2023-06-26 Nouveau dérivé de thalidomide et son procédé de production

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/008837 WO2023249470A1 (fr) 2022-06-24 2023-06-26 Nouveaux dérivés de pomalidomide et leur procédé de préparation

Country Status (2)

Country Link
KR (2) KR20240001071A (fr)
WO (2) WO2023249470A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137225A1 (fr) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Réactifs de méthylformyle substitué et procédé d'utilisation de ceux-ci pour modifier des propriétés physicochimiques et/ou pharmacocinétiques de composés
KR20190039567A (ko) * 2016-08-18 2019-04-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 신규 화합물
KR102185390B1 (ko) * 2020-04-17 2020-12-01 (주) 업테라 세포 투과성 세레블론 재조합 융합 단백질 및 이의 용도
WO2021077010A1 (fr) * 2019-10-17 2021-04-22 Arvinas Operations, Inc. Molécules bifonctionnelles contenant une fraction de liaison à l'ubiquitine ligase e3 liée à une fraction ciblant bcl6
WO2021152113A1 (fr) * 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Dérivés de 2,3-benzodiazépines substitués

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
EP3697436A1 (fr) * 2017-10-18 2020-08-26 Novartis AG Compositions et méthodes pour la dégradation sélective d'une protéine
CN113710661B (zh) * 2019-04-02 2022-11-22 上海睿跃生物科技有限公司 治疗癌症的化合物和方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137225A1 (fr) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Réactifs de méthylformyle substitué et procédé d'utilisation de ceux-ci pour modifier des propriétés physicochimiques et/ou pharmacocinétiques de composés
KR20190039567A (ko) * 2016-08-18 2019-04-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 신규 화합물
WO2021077010A1 (fr) * 2019-10-17 2021-04-22 Arvinas Operations, Inc. Molécules bifonctionnelles contenant une fraction de liaison à l'ubiquitine ligase e3 liée à une fraction ciblant bcl6
WO2021152113A1 (fr) * 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Dérivés de 2,3-benzodiazépines substitués
KR102185390B1 (ko) * 2020-04-17 2020-12-01 (주) 업테라 세포 투과성 세레블론 재조합 융합 단백질 및 이의 용도

Also Published As

Publication number Publication date
KR20240001071A (ko) 2024-01-03
KR20240001072A (ko) 2024-01-03
WO2023249470A1 (fr) 2023-12-28

Similar Documents

Publication Publication Date Title
US10730871B2 (en) Immunomodulators and immunomodulator conjugates
WO2018169282A2 (fr) Composition pharmaceutique contenant de l'atpif1 pour le traitement du diabète
KR100191989B1 (ko) 신규한 결정형의 무수7-((1알파,5알파,6알파)-6-아미노-3-아자비사이클로(3.1.0)헥스-3-일)-6-플루오로-1-(2,4-디플루오로페닐)-1,4-디하이드로-4-옥소-1,8-나프티리딘-3-카복실산 메탄설폰산 염
WO2018155997A1 (fr) Utilisation de peptide dérivé d'érythropoïétine au moyen de son effet sur la prévention de la lésion cellulaire
WO2023249469A1 (fr) Nouveau dérivé de thalidomide et son procédé de production
WO2020197016A1 (fr) Nouveau peptide antimicrobien dérivé du peptide pseudine-2, et son utilisation
BG104105A (bg) Алатрофлоксацинови парентерални състави
WO2019139388A1 (fr) Composition pharmaceutique comprenant un inhibiteur de la pi3-kinase et un inhibiteur de point de contrôle immunitaire, destinée à la prévention ou au traitement du cancer
WO2020116810A1 (fr) Composition pharmaceutique, comprenant un peptide inhibiteur contre la signalisation fas, destinée à la prévention ou au traitement de l'obésité, du foie gras, ou de la stéatohépatite
WO2023048453A1 (fr) Nanoparticules comprenant des dimères de médicament et leur utilisation
WO2023033276A1 (fr) Composition pharmaceutique comprenant un polymère de gamma-cyclodextrine et son utilisation
WO2022250416A1 (fr) Composition thérapeutique d'immuno-oncologie utilisant un adjuvant comprenant des lipopeptides et du poly (i:c)
WO2022260434A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie auto-immune
WO2019182322A1 (fr) Nouveau sel, son procédé de préparation et composition pharmaceutique le comprenant
WO2023249471A1 (fr) Nouveau dérivé d'amide immunorégulateur, son procédé de préparation et son utilisation
WO2023163539A1 (fr) Utilisation d'un nouveau dérivé de pomalidomide pour traiter des maladies cérébrales
WO2022050634A1 (fr) Peptide, composition cosmétique et composition pharmaceutique le comprenant
WO2021261870A1 (fr) Composition comprenant de la 6'-hydroxy justicidine-b pour prévenir, améliorer ou traiter des maladies allergiques
WO2023014082A1 (fr) Dérivé d'amide immunorégulateur ayant des propriétés de matériau améliorées
US11998606B2 (en) Compounds and methods for selective proteolysis of glucocorticoid receptors
WO2024205320A2 (fr) Composé à petites molécules présentant une activité de liaison au céréblon, et son utilisation
WO2023234743A1 (fr) Anticorps bispécifique comprenant un anticorps anti-tigit et son utilisation
WO2023195802A1 (fr) Nouvel agent immunothérapeutique anticancéreux à base de peptide
WO2023214836A1 (fr) Nouvel analogue de berbérine et son utilisation
WO2024035015A1 (fr) Composition pour la prévention, le soulagement ou le traitement de maladies neurodégénératives, comprenant de la fexofénadine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23827577

Country of ref document: EP

Kind code of ref document: A1